4D Paths Physics-Inspired QPOR Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
